ARTICLE
17 March 2023

Retail Pharmacies Face Difficult Balancing Act Relating To The Sale Of Mifepristone

SG
Shipman & Goodwin LLP

Contributor

Shipman & Goodwin’s value lies in our commitment -- to our clients, to the profession and to the community. We have one goal: to help our clients achieve their goals. How we accomplish it is simple: we devote our considerable experience and depth of knowledge to understand each client’s unique needs, business and industry, and then we develop solutions to meet those needs. Clients turn to us when they need a trusted advisor. With our invaluable awareness of each client’s challenges, we can counsel them at every step -- to keep their operations running smoothly, help them navigate complex business transactions, position them for future growth, or resolve business disputes. The success of our clients is of primary importance to us and our attorneys invest meaningful time getting to know the client's business and are skilled in the practice areas and industry sectors critical to that success. With more than 175 attorneys in offices throughout Connecticut, New York and in Washington, DC, we serve the needs of
On March 3, 2023, Walgreens, the second-largest pharmacy chain in the United States, announced that it will no longer be distributing the abortion medication mifepristone...
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

On March 3, 2023, Walgreens, the second-largest pharmacy chain in the United States, announced that it will no longer be distributing the abortion medication mifepristone, in 21 states including Alabama, Alaska, Arkansas, Florida, Georgia, Indiana, Iowa, Kansas, Kentucky, Louisiana, Mississippi, Missouri, Montana, North Dakota, Ohio, Oklahoma, South Carolina, South Dakota, Texas, Utah and West Virginia in response to letters signed by 21 state attorneys general warning that the company could face legal consequences for the sale of abortion pills in their respective states. Mifepristone is the first pill in a two-drug medication abortion regimen.  Walgreens' response has resulted in controversy on both sides of the aisle and provides a glimpse into the drugstore industry's attempts to deal with the chaotic cultural and legal state of the abortion debate.

The February 1, 2023 letter signed by 21 attorneys general (including in Kansas, Iowa, Montana and Alaska, states where abortion is currently legal, but where enacted or proposed laws create restrictions to the provision of abortion pills) cites the Comstock Act (previously discussed in our Jan. 4 alert) as a prohibition to sell or receive any drug used for abortion through the mail. The Department of Justice previously issued guidance on the matter on January 3, 2023, stating that the Comstock Act does not prohibit the mailing of medication abortion pills where the sender lacks the intent that the recipient will use them unlawfully. However, the letter disagrees with this assertion and states such an opinion would fail under the "slightest amount of scrutiny."

In response to Walgreens' decision, the California Department of General Services, at the behest of Governor Gavin Newsom, formally withdrew the planned renewal of a multi-million-dollar contract with Walgreens to procure pharmacy prescription drugs, primarily used by the California Department of Corrections and Rehabilitation and its correctional health care system.  While other large retail pharmacies such as Walmart, Rite Aid, Costco and CVS have yet to take such determinative action, with legal battles occurring in courts and legislatures nationwide, including a lawsuit currently being heard in the Northern District of Texas that could result in mifepristone being taken off the market entirely, these retailers will be forced to walk a fine line in selling permitted medicines and following state law.  The issue remains whether states that prohibit abortion will endeavor to prosecute retail pharmacies that sell mifepristone--or seek to obtain information about the prescribing providers.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

ARTICLE
17 March 2023

Retail Pharmacies Face Difficult Balancing Act Relating To The Sale Of Mifepristone

United States Food, Drugs, Healthcare, Life Sciences

Contributor

Shipman & Goodwin’s value lies in our commitment -- to our clients, to the profession and to the community. We have one goal: to help our clients achieve their goals. How we accomplish it is simple: we devote our considerable experience and depth of knowledge to understand each client’s unique needs, business and industry, and then we develop solutions to meet those needs. Clients turn to us when they need a trusted advisor. With our invaluable awareness of each client’s challenges, we can counsel them at every step -- to keep their operations running smoothly, help them navigate complex business transactions, position them for future growth, or resolve business disputes. The success of our clients is of primary importance to us and our attorneys invest meaningful time getting to know the client's business and are skilled in the practice areas and industry sectors critical to that success. With more than 175 attorneys in offices throughout Connecticut, New York and in Washington, DC, we serve the needs of
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More